ID   MP2K7_HUMAN             Reviewed;         419 AA.
AC   O14733; B2R9S5; D6W659; O14648; O14816; O60452; O60453; Q1PG43; Q8IY10;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   12-OCT-2022, entry version 210.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 7;
DE            Short=MAP kinase kinase 7;
DE            Short=MAPKK 7;
DE            EC=2.7.12.2;
DE   AltName: Full=JNK-activating kinase 2;
DE   AltName: Full=MAPK/ERK kinase 7;
DE            Short=MEK 7;
DE   AltName: Full=Stress-activated protein kinase kinase 4;
DE            Short=SAPK kinase 4;
DE            Short=SAPKK-4;
DE            Short=SAPKK4;
DE   AltName: Full=c-Jun N-terminal kinase kinase 2;
DE            Short=JNK kinase 2;
DE            Short=JNKK 2;
GN   Name=MAP2K7; Synonyms=JNKK2, MEK7, MKK7, PRKMK7, SKK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart, and Skeletal muscle;
RX   PubMed=9372971; DOI=10.1128/mcb.17.12.7407;
RA   Wu Z., Wu J., Jacinto E., Karin M.;
RT   "Molecular cloning and characterization of human JNKK2, a novel jun NH2-
RT   terminal kinase-specific kinase.";
RL   Mol. Cell. Biol. 17:7407-7416(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=9312068; DOI=10.1074/jbc.272.40.24751;
RA   Lu X., Nemoto S., Lin A.;
RT   "Identification of c-Jun NH2-terminal protein kinase (JNK)-activating
RT   kinase 2 as an activator of JNK but not p38.";
RL   J. Biol. Chem. 272:24751-24754(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, AND VARIANT PHE-259.
RC   TISSUE=Fetal kidney;
RX   PubMed=9535930; DOI=10.1074/jbc.273.15.9344;
RA   Foltz I.N., Gerl R.E., Wieler J.S., Luckach M., Salmon R.A., Schrader J.W.;
RT   "Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly
RT   conserved c-Jun N-terminal kinase/stress-activated protein kinase
RT   (JNK/SAPK) activated by environmental stresses and physiological stimuli.";
RL   J. Biol. Chem. 273:9344-9351(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), ACTIVITY REGULATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=16442502; DOI=10.1016/j.bbrc.2005.12.223;
RA   Michael L., Swantek J., Robinson M.J.;
RT   "Cloning and expression of human mitogen-activated protein kinase kinase
RT   7gamma1.";
RL   Biochem. Biophys. Res. Commun. 341:679-683(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN PHOSPHORYLATION OF
RP   MAPK8/JNK1 AND MAPK9/JNK2.
RA   Yang J., New L., Yong J., Han J., Su B.;
RT   "Molecular cloning of human JNKK2 reveals a novel kinase module for c-Jun
RT   N-terminal kinase activation.";
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-260 (ISOFORMS 1/4).
RX   PubMed=9207092; DOI=10.1073/pnas.94.14.7337;
RA   Tournier C., Whitmarsh A.J., Cavanagh J., Barrett T., Davis R.J.;
RT   "Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun
RT   NH2-terminal kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7337-7342(1997).
RN   [10]
RP   INTERACTION WITH MAPK8IP1/JIP1 AND MAPK8IP2/JIP2.
RX   PubMed=10490659; DOI=10.1128/mcb.19.10.7245;
RA   Yasuda J., Whitmarsh A.J., Cavanagh J., Sharma M., Davis R.J.;
RT   "The JIP group of mitogen-activated protein kinase scaffold proteins.";
RL   Mol. Cell. Biol. 19:7245-7254(1999).
RN   [11]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family members
RT   to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [12]
RP   INTERACTION WITH MAPK8IP3/JIP3.
RX   PubMed=12189133; DOI=10.1074/jbc.m202004200;
RA   Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M.,
RA   Yoshioka K., Ichijo H.;
RT   "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK
RT   signaling pathway. A new mode of regulation of the MAP kinase cascade.";
RL   J. Biol. Chem. 277:40703-40709(2002).
RN   [13]
RP   DOMAIN.
RX   PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001;
RA   Takekawa M., Tatebayashi K., Saito H.;
RT   "Conserved docking site is essential for activation of mammalian MAP kinase
RT   kinases by specific MAP kinase kinase kinases.";
RL   Mol. Cell 18:295-306(2005).
RN   [14]
RP   INTERACTION WITH VRK2.
RX   PubMed=18286207; DOI=10.1371/journal.pone.0001660;
RA   Blanco S., Sanz-Garcia M., Santos C.R., Lazo P.A.;
RT   "Modulation of interleukin-1 transcriptional response by the interaction
RT   between VRK2 and the JIP1 scaffold protein.";
RL   PLoS ONE 3:E1660-E1660(2008).
RN   [15]
RP   REVIEW ON ACTIVITY REGULATION.
RX   PubMed=17496909; DOI=10.1038/sj.onc.1210392;
RA   Raman M., Chen W., Cobb M.H.;
RT   "Differential regulation and properties of MAPKs.";
RL   Oncogene 26:3100-3112(2007).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   REVIEW ON FUNCTION.
RX   PubMed=20801953; DOI=10.1093/jb/mvq098;
RA   Asaoka Y., Nishina H.;
RT   "Diverse physiological functions of MKK4 and MKK7 during early
RT   embryogenesis.";
RL   J. Biochem. 148:393-401(2010).
RN   [18]
RP   INTERACTION WITH RASSF7.
RX   PubMed=21278800; DOI=10.1038/cdd.2010.137;
RA   Takahashi S., Ebihara A., Kajiho H., Kontani K., Nishina H., Katada T.;
RT   "RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting the
RT   activity of phosphorylated-MKK7.";
RL   Cell Death Differ. 18:645-655(2011).
RN   [19]
RP   REVIEW ON REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008;
RA   Haeusgen W., Herdegen T., Waetzig V.;
RT   "The bottleneck of JNK signaling: molecular and functional characteristics
RT   of MKK4 and MKK7.";
RL   Eur. J. Cell Biol. 90:536-544(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   FUNCTION.
RX   PubMed=28111074; DOI=10.1016/j.cell.2016.12.044;
RA   Huang Y.A., Zhou B., Wernig M., Suedhof T.C.;
RT   "ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and
RT   Abeta Secretion.";
RL   Cell 168:427-441(2017).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 101-405.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of human mitogen-activated protein kinase kinase 7
RT   activated mutant (s287d, t291d).";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [24]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-118; CYS-138; CYS-162; HIS-162 AND
RP   THR-195.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. Essential
CC       component of the stress-activated protein kinase/c-Jun N-terminal
CC       kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the
CC       only known kinase to directly activate the stress-activated protein
CC       kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3.
CC       MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation,
CC       but they differ in their preference for the phosphorylation site in the
CC       Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of
CC       the Tyr residue and MAP2K7/MKK7 for the Thr residue. The
CC       monophosphorylation of JNKs on the Thr residue is sufficient to
CC       increase JNK activity indicating that MAP2K7/MKK7 is important to
CC       trigger JNK activity, while the additional phosphorylation of the Tyr
CC       residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific
CC       role in JNK signal transduction pathway activated by pro-inflammatory
CC       cytokines. The MKK/JNK signaling pathway is also involved in
CC       mitochondrial death signaling pathway, including the release cytochrome
CC       c, leading to apoptosis. Part of a non-canonical MAPK signaling
CC       pathway, composed of the upstream MAP3K12 kinase and downstream MAP
CC       kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated
CC       transcription of APP in response to APOE (PubMed:28111074).
CC       {ECO:0000269|PubMed:28111074, ECO:0000269|PubMed:9312068,
CC       ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,
CC       ECO:0000269|Ref.5}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation by specific MAP
CC       kinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3, MAP3K11/MLK3
CC       and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,
CC       ECO:0000269|PubMed:9312068}.
CC   -!- SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its D domain)
CC       with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3 (By
CC       similarity). Interacts (via its DVD domain) with MAP3Ks activators like
CC       MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity). Interacts with
CC       MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3 scaffold proteins.
CC       Interacts with RASSF7, the interaction promotes phosphorylation. Found
CC       in a complex with SH3RF1, RAC1, MAP3K11/MLK3, MAPK8IP1/JIP1 and
CC       MAPK8/JNK1. Found in a complex with SH3RF1, RAC2, MAP3K7/TAK1,
CC       MAPK8IP1/JIP1, MAPK8/JNK1 and MAPK9/JNK2 (By similarity).
CC       {ECO:0000250|UniProtKB:Q8CE90, ECO:0000269|PubMed:10490659,
CC       ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,
CC       ECO:0000269|PubMed:21278800}.
CC   -!- INTERACTION:
CC       O14733; O15519-1: CFLAR; NbExp=2; IntAct=EBI-492605, EBI-4567563;
CC       O14733; O75293: GADD45B; NbExp=8; IntAct=EBI-492605, EBI-448187;
CC       O14733; P08238: HSP90AB1; NbExp=2; IntAct=EBI-492605, EBI-352572;
CC       O14733; Q5S007: LRRK2; NbExp=3; IntAct=EBI-492605, EBI-5323863;
CC       O14733; O43318: MAP3K7; NbExp=3; IntAct=EBI-492605, EBI-358684;
CC       O14733; Q9UQF2: MAPK8IP1; NbExp=5; IntAct=EBI-492605, EBI-78404;
CC       O14733-2; P45983: MAPK8; NbExp=3; IntAct=EBI-492627, EBI-286483;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=A;
CC         IsoId=O14733-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=O14733-2; Sequence=VSP_004883;
CC       Name=3; Synonyms=gamma1;
CC         IsoId=O14733-3; Sequence=VSP_022309;
CC       Name=4;
CC         IsoId=O14733-4; Sequence=VSP_022310;
CC   -!- TISSUE SPECIFICITY: Ubiquitous; with highest level of expression in
CC       skeletal muscle. Isoform 3 is found at low levels in placenta, fetal
CC       liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,
CC       ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.
CC   -!- DOMAIN: The DVD domain (residues 377-400) contains a conserved docking
CC       site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD
CC       sites bind to their specific upstream MAP kinase kinase kinases
CC       (MAP3Ks) and are essential for activation.
CC       {ECO:0000269|PubMed:15866172}.
CC   -!- DOMAIN: The D domain (residues 37-57) contains a conserved docking site
CC       and is required for the binding to MAPK substrates.
CC       {ECO:0000269|PubMed:15866172}.
CC   -!- PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAP kinase
CC       kinase kinases (MAP3Ks). {ECO:0000250}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to intron retention.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB97813.1; Type=Erroneous termination; Note=Extended C-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAB97813.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF014401; AAB88048.1; -; mRNA.
DR   EMBL; AF006689; AAB97813.1; ALT_SEQ; mRNA.
DR   EMBL; AF013588; AAC16272.1; -; mRNA.
DR   EMBL; AF013589; AAC16273.1; -; mRNA.
DR   EMBL; DQ445915; ABE03013.1; -; mRNA.
DR   EMBL; AF022805; AAC26142.1; -; mRNA.
DR   EMBL; AK313899; BAG36622.1; -; mRNA.
DR   EMBL; CH471139; EAW68964.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW68968.1; -; Genomic_DNA.
DR   EMBL; BC038295; AAH38295.1; -; mRNA.
DR   EMBL; AF003199; AAB63374.1; -; mRNA.
DR   CCDS; CCDS42491.1; -. [O14733-1]
DR   CCDS; CCDS74277.1; -. [O14733-3]
DR   CCDS; CCDS74278.1; -. [O14733-4]
DR   RefSeq; NP_001284484.1; NM_001297555.1. [O14733-3]
DR   RefSeq; NP_001284485.1; NM_001297556.1. [O14733-4]
DR   RefSeq; NP_660186.1; NM_145185.3. [O14733-1]
DR   PDB; 2DYL; X-ray; 2.45 A; A=101-405.
DR   PDB; 3WZU; X-ray; 3.01 A; A=103-419.
DR   PDB; 4UX9; X-ray; 2.34 A; F/G/H/I=37-48.
DR   PDB; 5B2K; X-ray; 2.75 A; A=103-419.
DR   PDB; 5B2L; X-ray; 2.10 A; A=103-419.
DR   PDB; 5B2M; X-ray; 3.06 A; A=103-419.
DR   PDB; 5Y8U; X-ray; 2.92 A; A=103-419.
DR   PDB; 5Y90; X-ray; 1.30 A; A=103-419.
DR   PDB; 5Z1D; X-ray; 2.28 A; A=102-419.
DR   PDB; 5Z1E; X-ray; 2.30 A; A=102-419.
DR   PDB; 6IB0; X-ray; 2.60 A; A=101-408.
DR   PDB; 6IB2; X-ray; 2.10 A; A=101-408.
DR   PDB; 6QFL; X-ray; 2.20 A; A=101-408.
DR   PDB; 6QFR; X-ray; 2.30 A; A=101-408.
DR   PDB; 6QFT; X-ray; 2.70 A; A=101-408.
DR   PDB; 6QG4; X-ray; 2.30 A; A=111-408.
DR   PDB; 6QG7; X-ray; 2.10 A; A=101-408.
DR   PDB; 6QHO; X-ray; 2.70 A; A=111-408.
DR   PDB; 6QHR; X-ray; 2.52 A; A=111-408.
DR   PDB; 6YFZ; X-ray; 1.90 A; A=100-405.
DR   PDB; 6YG0; X-ray; 2.00 A; A=100-405.
DR   PDB; 6YG1; X-ray; 2.22 A; A/B/C=60-405.
DR   PDB; 6YG2; X-ray; 2.00 A; A=100-405.
DR   PDB; 6YG3; X-ray; 2.05 A; A=100-405.
DR   PDB; 6YG4; X-ray; 2.30 A; A=100-405.
DR   PDB; 6YG5; X-ray; 2.40 A; A=100-405.
DR   PDB; 6YG6; X-ray; 2.15 A; A/B=100-405.
DR   PDB; 6YG7; X-ray; 2.20 A; A/B=100-405.
DR   PDB; 6YZ4; X-ray; 1.70 A; A=100-405.
DR   PDB; 7CBX; X-ray; 2.06 A; A=103-419.
DR   PDBsum; 2DYL; -.
DR   PDBsum; 3WZU; -.
DR   PDBsum; 4UX9; -.
DR   PDBsum; 5B2K; -.
DR   PDBsum; 5B2L; -.
DR   PDBsum; 5B2M; -.
DR   PDBsum; 5Y8U; -.
DR   PDBsum; 5Y90; -.
DR   PDBsum; 5Z1D; -.
DR   PDBsum; 5Z1E; -.
DR   PDBsum; 6IB0; -.
DR   PDBsum; 6IB2; -.
DR   PDBsum; 6QFL; -.
DR   PDBsum; 6QFR; -.
DR   PDBsum; 6QFT; -.
DR   PDBsum; 6QG4; -.
DR   PDBsum; 6QG7; -.
DR   PDBsum; 6QHO; -.
DR   PDBsum; 6QHR; -.
DR   PDBsum; 6YFZ; -.
DR   PDBsum; 6YG0; -.
DR   PDBsum; 6YG1; -.
DR   PDBsum; 6YG2; -.
DR   PDBsum; 6YG3; -.
DR   PDBsum; 6YG4; -.
DR   PDBsum; 6YG5; -.
DR   PDBsum; 6YG6; -.
DR   PDBsum; 6YG7; -.
DR   PDBsum; 6YZ4; -.
DR   PDBsum; 7CBX; -.
DR   AlphaFoldDB; O14733; -.
DR   SMR; O14733; -.
DR   BioGRID; 111595; 118.
DR   IntAct; O14733; 111.
DR   MINT; O14733; -.
DR   STRING; 9606.ENSP00000381070; -.
DR   BindingDB; O14733; -.
DR   ChEMBL; CHEMBL3530; -.
DR   DrugCentral; O14733; -.
DR   GuidetoPHARMACOLOGY; 2068; -.
DR   iPTMnet; O14733; -.
DR   MetOSite; O14733; -.
DR   PhosphoSitePlus; O14733; -.
DR   BioMuta; MAP2K7; -.
DR   CPTAC; CPTAC-822; -.
DR   CPTAC; CPTAC-823; -.
DR   EPD; O14733; -.
DR   jPOST; O14733; -.
DR   MassIVE; O14733; -.
DR   MaxQB; O14733; -.
DR   PaxDb; O14733; -.
DR   PeptideAtlas; O14733; -.
DR   PRIDE; O14733; -.
DR   ProteomicsDB; 48192; -. [O14733-1]
DR   ProteomicsDB; 48193; -. [O14733-2]
DR   ProteomicsDB; 48194; -. [O14733-3]
DR   ProteomicsDB; 48195; -. [O14733-4]
DR   Antibodypedia; 1176; 771 antibodies from 41 providers.
DR   DNASU; 5609; -.
DR   Ensembl; ENST00000397979.4; ENSP00000381066.3; ENSG00000076984.18. [O14733-1]
DR   Ensembl; ENST00000397981.7; ENSP00000381068.3; ENSG00000076984.18. [O14733-4]
DR   Ensembl; ENST00000397983.7; ENSP00000381070.2; ENSG00000076984.18. [O14733-3]
DR   GeneID; 5609; -.
DR   KEGG; hsa:5609; -.
DR   MANE-Select; ENST00000397979.4; ENSP00000381066.3; NM_145185.4; NP_660186.1.
DR   UCSC; uc002mit.4; human. [O14733-1]
DR   CTD; 5609; -.
DR   DisGeNET; 5609; -.
DR   GeneCards; MAP2K7; -.
DR   HGNC; HGNC:6847; MAP2K7.
DR   HPA; ENSG00000076984; Low tissue specificity.
DR   MIM; 603014; gene.
DR   neXtProt; NX_O14733; -.
DR   OpenTargets; ENSG00000076984; -.
DR   PharmGKB; PA284; -.
DR   VEuPathDB; HostDB:ENSG00000076984; -.
DR   eggNOG; KOG0983; Eukaryota.
DR   GeneTree; ENSGT00940000158914; -.
DR   HOGENOM; CLU_000288_63_23_1; -.
DR   InParanoid; O14733; -.
DR   OMA; CFGYFIT; -.
DR   OrthoDB; 688282at2759; -.
DR   PhylomeDB; O14733; -.
DR   TreeFam; TF350701; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   PathwayCommons; O14733; -.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   SignaLink; O14733; -.
DR   SIGNOR; O14733; -.
DR   BioGRID-ORCS; 5609; 78 hits in 1116 CRISPR screens.
DR   ChiTaRS; MAP2K7; human.
DR   EvolutionaryTrace; O14733; -.
DR   GeneWiki; MAP2K7; -.
DR   GenomeRNAi; 5609; -.
DR   Pharos; O14733; Tchem.
DR   PRO; PR:O14733; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O14733; protein.
DR   Bgee; ENSG00000076984; Expressed in buccal mucosa cell and 187 other tissues.
DR   Genevisible; O14733; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0008545; F:JUN kinase kinase activity; ISS:ARUK-UCL.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; ISS:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0072709; P:cellular response to sorbitol; IEA:Ensembl.
DR   GO; GO:0090398; P:cellular senescence; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007254; P:JNK cascade; ISS:BHF-UCL.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; ISS:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:2000671; P:regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0009408; P:response to heat; IDA:UniProtKB.
DR   GO; GO:0006970; P:response to osmotic stress; IDA:UniProtKB.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0009411; P:response to UV; IDA:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB.
DR   DisProt; DP00841; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Coiled coil; Cytoplasm; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Stress response; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..419
FT                   /note="Dual specificity mitogen-activated protein kinase
FT                   kinase 7"
FT                   /id="PRO_0000086388"
FT   DOMAIN          120..380
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          18..76
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          37..57
FT                   /note="D domain"
FT                   /evidence="ECO:0000250"
FT   REGION          377..400
FT                   /note="DVD domain"
FT   COILED          2..30
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        18..33
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        243
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         126..134
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         149
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            44..45
FT                   /note="Cleavage; by anthrax lethal factor"
FT   SITE            76..77
FT                   /note="Cleavage; by anthrax lethal factor"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         271
FT                   /note="Phosphoserine; by MAP3K"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         275
FT                   /note="Phosphothreonine; by MAP3K"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         411
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         42
FT                   /note="T -> IIVITLSPAPAPSQRAA (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16442502"
FT                   /id="VSP_022309"
FT   VAR_SEQ         111
FT                   /note="Q -> QVPPSLWRGEGGGPARLDPSWERQWGAGGGGRAPGTLQPSLSSQ
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9535930"
FT                   /id="VSP_004883"
FT   VAR_SEQ         312
FT                   /note="L -> LPCPSPSQ (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_022310"
FT   VARIANT         118
FT                   /note="N -> S (in dbSNP:rs56316660)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040825"
FT   VARIANT         138
FT                   /note="R -> C (in dbSNP:rs56106612)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040826"
FT   VARIANT         162
FT                   /note="R -> C (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040827"
FT   VARIANT         162
FT                   /note="R -> H (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040828"
FT   VARIANT         195
FT                   /note="A -> T (in dbSNP:rs55800262)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040829"
FT   VARIANT         259
FT                   /note="L -> F (in dbSNP:rs1053566)"
FT                   /evidence="ECO:0000269|PubMed:9535930"
FT                   /id="VAR_029890"
FT   CONFLICT        94
FT                   /note="Q -> H (in Ref. 2; AAB97813)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        106
FT                   /note="L -> P (in Ref. 4; ABE03013)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        133
FT                   /note="Q -> P (in Ref. 2; AAB97813)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        142
FT                   /note="T -> N (in Ref. 1; AAB88048)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        407
FT                   /note="S -> N (in Ref. 2; AAB97813)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        415
FT                   /note="L -> LG (in Ref. 2; AAB97813)"
FT                   /evidence="ECO:0000305"
FT   HELIX           87..100
FT                   /evidence="ECO:0007829|PDB:6YG1"
FT   STRAND          104..108
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          111..115
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           117..119
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          120..126
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          129..138
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   TURN            140..142
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          145..152
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           157..171
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   TURN            172..175
FT                   /evidence="ECO:0007829|PDB:6YFZ"
FT   STRAND          182..187
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          189..196
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           203..210
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           216..237
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           246..248
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          257..259
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   TURN            262..265
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           281..283
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           286..289
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          294..296
FT                   /evidence="ECO:0007829|PDB:6YZ4"
FT   HELIX           302..317
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   TURN            321..324
FT                   /evidence="ECO:0007829|PDB:6YZ4"
FT   HELIX           328..337
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   STRAND          345..347
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           351..360
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           365..367
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           371..374
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           378..385
FT                   /evidence="ECO:0007829|PDB:5Y90"
FT   HELIX           390..401
FT                   /evidence="ECO:0007829|PDB:5Y90"
SQ   SEQUENCE   419 AA;  47485 MW;  F1B22E050F54299A CRC64;
     MAASSLEQKL SRLEAKLKQE NREARRRIDL NLDISPQRPR PTLQLPLAND GGSRSPSSES
     SPQHPTPPAR PRHMLGLPST LFTPRSMESI EIDQKLQEIM KQTGYLTIGG QRYQAEINDL
     ENLGEMGSGT CGQVWKMRFR KTGHVIAVKQ MRRSGNKEEN KRILMDLDVV LKSHDCPYIV
     QCFGTFITNT DVFIAMELMG TCAEKLKKRM QGPIPERILG KMTVAIVKAL YYLKEKHGVI
     HRDVKPSNIL LDERGQIKLC DFGISGRLVD SKAKTRSAGC AAYMAPERID PPDPTKPDYD
     IRADVWSLGI SLVELATGQF PYKNCKTDFE VLTKVLQEEP PLLPGHMGFS GDFQSFVKDC
     LTKDHRKRPK YNKLLEHSFI KRYETLEVDV ASWFKDVMAK TESPRTSGVL SQPHLPFFR
//
